Oncimmune Holdings PLC Appointment of Senior VP, MA & Reimbursement
03 April 2017 - 4:01PM
RNS Non-Regulatory
TIDMONC
Oncimmune Holdings PLC
03 April 2017
3 April 2017
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Appointment of Senior Vice President, Market Access &
Reimbursement
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer
detection company developing and commercialising its proprietary
EarlyCDT(R) platform technology, today announces the appointment of
Shane Smith as Senior Vice President, Market Access &
Reimbursement Oncimmune (USA).
Shane is a commercial leader with more than 15 years' experience
within market access, reimbursement and sales management. He has
extensive knowledge of the US market and a proven track record in
sales force development, training, government accounts, Managed
Care Organisations and laboratory contracting. Shane is highly
experienced in molecular diagnostic contracting with national,
regional and local health sales plans, as well as reference
laboratories and hospital systems of all sizes. In addition, he has
successfully managed several high dose immunotherapy centres
focused on oncology. His experience also covers recruitment,
managing and developing field based talent, conducting coaching,
training, and providing directional leadership for both diagnostic
and therapeutic products.
Most recently, Shane was Vice President, Market Access &
Reimbursement, Lineagen, Inc. in Salt Lake City, UT where he
focused on coverage and value-based reimbursement for Lineagen's
portfolio. He developed and executed Lineagen's market access and
payor strategies for its optimized chromosomal microarray test and
its gene sequencing test. Prior to Lineagen, Shane led Market
Access, Payer Markets, & Reimbursement for KEW Group where he
managed reimbursement contracts and billing policies, working with
organisations, business partners, institutions, commercial and
government payors to establish coverage and value-based
reimbursement for their proprietary next-generation sequencing
solid tumor gene test. Earlier in his career, Shane held multiple
sales roles with Prometheus Laboratories as well as Novartis
Pharmaceuticals Corp.
Geoffrey Hamilton-Fairley, CEO of Oncimmune, said: "I am
delighted to welcome Shane to Oncimmune. His appointment means that
we have now completed the management team development we outlined
at the time of our IPO. With Shane's wealth of experience adding to
our already strong team, I am even more confident we have the
necessary sales structure in place to fully exploit our
EarlyCDT(R)-Lung test as well as looking to develop and bring to
market other diagnostic tests from across the EarlyCDT(R)
platform."
Commenting on his appointment, Shane Smith said:
"EarlyCDT(R)-Lung has the potential to detect cancer up to four
years earlier than other methods and I hope to use my previous
experience in commercialising multiple diagnostic devices to make
sure that this test becomes commercially available to as many
patients and payors as possible. I am excited about my future at
Oncimmune and look forward to sharing in its success."
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Phil Walker, Giles Balleny, Dominic Wilson
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
About Oncimmune
Oncimmune is a leading early cancer detection company developing
and commercialising its proprietary EarlyCDT(R) platform
technology. Oncimmune has pioneered the development of autoantibody
tests that can detect cancer up to four years earlier than other
methods and can be applied to a very wide range of solid tumour
types. The Company's first product, EarlyCDT(R)-Lung, was launched
in 2012, as a CLIA test in the USA and since then over 150,000
commercial tests have been sold. EarlyCDT(R)-Lung is available
through physicians in the US and also privately in the UK and other
regions. EarlyCDT(R)-Lung is being used in the largest ever
randomised trial for the early detection of lung cancer using
biomarkers, the National Health Service (NHS) Scotland ECLS study
of 12,000 high-risk smokers. EarlyCDT(R) tests for liver and
ovarian cancer are in development.
Oncimmune, headquartered in Nottingham, United Kingdom with
testing facilities in the US, joined AIM in May 2016 under the
ticker ONC.L. For more information, visit www.oncimmune.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALFFIFSLIFIID
(END) Dow Jones Newswires
April 03, 2017 02:01 ET (06:01 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024